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osting by EAbstract Hospital-acquired pneumonia (HAP) is the most frequent hospital-acquired infection in
critically ill patients. National Nosocomial Infections Surveillance (NNIS) system reported that
HAPaccounts for asmuch as 31%of all nosocomial infections acquired inmedical intensive care units
(ICU). The increasing incidence of infections caused by antibiotic-resistant pathogens contributes to a
highmortality rate, longer ICU stay and higher costs. In this study, we aimed to identify the incidence
of HAP, the associated risk factors, and its effect on outcome. We evaluated as well the usefulness of
multiplex polymerase chain reaction (m-PCR) as a novel tool for emergency diagnosis of HAP.
We examined all consecutive admissions to Pediatric ICU from February 2010 to August 2010.
Patients were diagnosed to have HAP when their Clinical Pulmonary Infection Score (CPIS) index
was more than 6. Blood and endotracheal aspirate (ETA) were tested for bacterial pathogens by
microbiological cultures and multiplex PCR simultaneously for all enrolled patients.
Twenty-ﬁve patients out of 90 admissions (27.7%) developed HAP during the observation period,
with incidence rate of 13 per 1000 patient-days and overall mortality of 56%. Gastro-esophagealas El-Akad Street, Nasr City,
l.com (M.G.E. Mansour).
y. Production and hosting by
Shams University.
lsevier
100 M.G.E. Mansour, S. Bendaryreﬂux disease (GERD), mechanical ventilation (MV), endotracheal re-intubation and sedation were
themain recorded risk factors forHAP. ETA had better diagnostic yield than blood specimens for the
diagnosis of HAP.Multiplex-PCR showed better sensitivity and positive predictive value than bacte-
rial culture for etiological diagnosis of HAP. Acinetobacter and Klebsiella pneumoniae were the most
common identiﬁed pathogens. In conclusion, hospital-acquired pneumonia adversely affects patients
outcome in our setting, for which we should manipulate the identiﬁed modiﬁable risk factors. More-
over, m-PCR permits simultaneous detection of several bacterial pathogens in a single reaction which
can optimize the emergency diagnosis ofHAPand can improve etiology-directed clinicalmanagement
of bacterial pneumonia.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.Box 1. Centers for Disease Control and Prevention criteria
for nosocomial pneumonia (adult)
Radiology
Two or more serial chest radiographsa with at least
one of the following:
New or progressive and persistent inﬁltrate
Consolidation
Cavitation
Signs/symptoms/laboratory
At least one of the following:
Fever (>38 C or >100.4 F) with no other rec-
ognized cause
Leukopenia (<4000 white blood cell count per
microliter [WBC/lL] or leukocytosis
(>12,000 WBC/ll)
For adults 70 years old or older, mental status
changes with no other recognized cause
And at least two of the following:
New onset of purulent sputum, or change in
character of sputum, or increased respiratory
secretions, or increased suctioning requirements
New-onset or worsening cough, or dyspnea, or
tachycardia
Rales or bronchial breath sounds
Worsening gas exchange (PaO2/fraction of
inspired oxygen [FiO2] 6240), increased oxygen
requirements, or increased ventilation demand
aIn patients with no underlying pulmonary or cardiac
disease, one deﬁnitive radiograph is acceptable.
From Centers for Disease Control and Prevention.
Available at: www.cdc.gov/ncidod/hop/nnis/members/
pneumonia/ﬁnal/pneumoniacriteriav1. Accessed May 1,
2008. Adapted from [6].1. Introduction
Several reports published recently conﬁrm that hospital-ac-
quired pneumonia (HAP) remains to be a major medical prob-
lem inmost European countries, and in theUnited States despite
the advances in the quality of patient care, availability of effec-
tive antibiotics, complex technological diagnostic facilities and
awareness in infection control measures [1]. Its occurrence rep-
resents additional cost, morbidity and most importantly, mor-
tality among patients hospitalized initially for other reasons.
The reported frequency varies with the deﬁnition, type of
ICU, patients’ population, and antibiotic policies [2].
Etiologic diagnosis of HAP is considered a microbiological
emergency because of its impact on disease associated morbid-
ity and mortality and antibiotic management, so rapid diag-
nostic information is clearly more beneﬁcial to patients than
more complete but delayed information. Multiplex-PCR is a
universal technique making it possible to identify more than
one micro-organism, in less than one hour directly from pa-
tient specimens making it very speciﬁc and time-saving for
diagnosis [3,4].
The Egyptian data on HAP are lacking. The aim of this
study was to determine the incidence of hospital-acquired
pneumonia, to identify risk factors associated with its develop-
ment, and describe its effect on hospital stay and mortality in
critically ill patients. Also in our study, we aimed to evaluate
the usefulness of m-PCR as an emergency tool for the diagno-
sis of HAP compared to bacterial culture.
2. Patients and methods
2.1. Study setting
This study was conducted in pediatric intensive care unit
(PICU) of Ain Shams University Hospital, which is a multidis-
ciplinary medical ICU with 10 beds and average occupancy
rate of 80% during the time of the study.
2.2. Patients’ data acquisition
Demographic variables such as gender, age, underlying disease
together with the patients’ clinical data, degree of critical ill-
ness by PELOD score [5], risk factors of pneumonia, length
of PICU stay, duration of mechanical ventilation, and antibi-
otic regimen were collected from patients’ records after getting
the parents’ consent and the approval of ethical committee.
Data collection began within 24 h from the time of admission
to the ICU and continued until the diagnosis of HAP was
made or until the third day after the transfer out of the PICU.2.3. Patients’ enrollment
All admitted patients were observed daily for the diagnosis of
HAP according to The Clinical Pulmonary Infection Score
(CPIS). The method of establishing the diagnosis of HAP
remains controversial and no method has emerged as the gold
standard. For these reasons, clinical guidelines are available to
aid in decision making about acquisition of hospital-acquired
pneumonia. The Centers for Disease Control and Prevention
and the National Healthcare Safety Network have developed
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into account clinical factors, such as fever and leukocytosis,
as well as radiological criteria, including persistent new ﬁnd-
ings on chest radiograph (Box 1) [6].
We used the Clinical Pulmonary Infection Score (CPIS) to
help quantify clinical ﬁndings and represent a ‘‘weighted ap-
proach’’ to the clinical diagnosis of HAP. This scoring system
includes both clinical and radiological factors that increase the
likelihood of the presence of nosocomial pneumonia. Point
values are assigned to each criteria and a sum is calculated.
Traditionally, a threshold score of more than six has been used
to diagnose pneumonia (Table 1) [7].2.4. Microbiological assessment
2.4.1. Clinical specimens
Both endotracheal aspirate (ETA) and blood samples were
screened from enrolled patients. These specimens were tested
against important and common bacterial pathogens by both
bacterial culture and multiplex Polymerase Chain Reaction
(m-PCR).2.4.2. Bacterial cultures
Specimens were obtained and sent to the laboratory within
one hour of collection. They were decontaminated and centri-
fuged before inoculation. Inoculation was on blood agar and
chocolate agar for blood specimens and further on McConkey
agar for ETA. Specimens were incubated for one week and
observed for colonies every day in ETA and every 48 h in
blood specimens. Colonies were identiﬁed by gram stain and
biochemical proﬁle. Infection was deﬁned by semi-quantita-
tive count of more than 105 CFU/ml. Antibiotic sensitivity
test was done for positive isolates using disk diffusion method
according to the National Committee for clinical Laboratory
standards (NCCLS) Clinical and Laboratory Standards
Institute (CLSI). Performance standards for antimicrobial
disc susceptibility test: Approved standard-Ninth edition
(200).Table 1 Modiﬁed Clinical Pulmonary Infection Score.
Measurement Points
0 1
Temperature (C) 36.5–38.4 38.5–38.9
Peripheral white blood
cell count
4000–11,000 <4000 or >
bands: add 1
Tracheal secretions None Nonpurulen
Chest radiograph No inﬁltrate Diﬀuse or p
inﬁltrate
Progression of inﬁltrate
from prior radiographs
None
Culture of endotracheal
tube suction
No growth/light
growth
Heavy grow
on gram sta
Oxygenation (PaO2
fraction of inspired
oxygen [FiO2])
>240 or acute
respiratory distress
syndrome
Adapted from Swoboda et al. [7].2.4.3. Multiplex PCR
Collected specimens were assessed for seven bacterial agents;
that are considered serious causative pathogens for HAPworld-
wide. These organisms are sharing some physical properties
during their processing for PCR (Acinetobacter was not
involved in the panel because it has different incubation temper-
ature than the selected primers for the other seven organisms).
DNA extraction: DNA was extracted from the samples using
MagNA pure Compact Nucleic Acid Isolation Kit I (Cat.
No. o3730964001); supplied by (Roche, Germany). Ampliﬁca-
tion by PCR: This was done by Light Cycler-DNA Ampliﬁca-
tion Kit SYBR Green I (Cat. No. 2015137). The kit used
Light Cycler 2.0 System (Roche, Germany). Primers: Primers
were non-labeled forward primers and biotin-labeled reverse
primers with horseradish peroxidase-labeled probes. Primers
forMycoplasmapneumoniae, Chlamydiapneumoniae, Legionella
pneumophilia, Staphylococcus aureus, and Streptococcus pneu-
moniae were selected according to Kumar et al. [8]. Primers
for Klebsiella pneumoniae were made according to Kurupati
et al. [9]. Primers for Pseudomonas aeruginosa were chosen
according to Qin et al. [10].2.5. Statistical analysis
Analysis of data was done by IBM computer using SPSS 12-
USA. Description of quantitative variables is expressed as
mean and standard deviation (SD). Description of qualitative
variables is expressed as number and percentage. The Wilco-
xon’s signed-rank test compared the difference between culture
and PCR in different study specimens. There is no gold stan-
dard for the diagnosis of VAP or HAP in pediatric patients;
therefore, we used a clinical deﬁnition of HAP based on Clin-
ical Pulmonary Infection Score of NNIS (National Nosoco-
mial Infections Surveillance) age-speciﬁc guidelines.
Sensitivity and speciﬁcity of m-PCR and bacterial culture were
referred to CPIS as the clinical gold standard for the diagnosis
of HAP (CPISP 6 is the cut-off for diagnosis of HAP) [7].
Sensitivity of culture or m-PCR represents the proportion
of patients with HAP who were test positive. Speciﬁcity is2
636.4 or P39
11,000 (>50%
extra point)
t Purulent
atchy Localized inﬁltrate
Progression (acute respiratory distress
syndrome or congestive heart failure
thought unlikely)
th (some bacteria
in: add 1 extra point)
6240 and no acute respiratory
distress syndrome
Table 2 Characteristics of patients and comparison of patients who developed and did not develop hospital-associated pneumonia
(HAP).
Characteristics All patients (n= 90) Patients with HAP (n= 25) Patients without HAP (n= 65) p-Value
Patients-related characteristic
Mean age ± SD, months 21 ± 18.7 22.5 ± 19.8 23.6 ± 18 0.61
Male sex, n (%) 44 (49%) 19 (76%) 25 (38%) <0.01
Median PELOD Score (interquartile range) 24 (9–39) 25 (10–42) 23 (9–39) 0.71
Admission diagnosis, n (%)
Pulmonary diseases 11 (12%) 3 (12%) 8 (13%) 0.96
Cardiac diseases 13 (14%) 3 (12%) 10 (15%) 0.69
Neurologic diseases 43 (48%) 13 (52%) 30 (46%) 0.61
Acute gastrointestinal infections 9 (1%) 3 (12%) 6 (9%) 0.69
Postoperative 14 (16%) 3 (12%) 11 (17%) 0.67
Outcome
Length of PICU stay, days; mean ± SD 34 ± 47 44 ± 45 22 ± 34 <0.05
Length of MV, days; mean ± SD 30 ± 35 39 ± 43 22 ± 28 <0.01
Predicted mortality rate %, (range) 34% (1–99) 34% (1–90) 36% (2–98) –
Actual mortality, n (%) 26 (29%) 11 (44%) 15 (23%) 0.04
Risk factors for HAP, n (%)
Mechanical ventilation 32 (36%) 19 (76%) 13 (20%) <0.01
Re-intubation 13 (14%) 9 (36%) 4 (6%) <0.001
Sedation 26 (29%) 13 (52%) 13 (20%) <0.01
Nasogastric feeding 32 (36%) 17 (68%) 15 (23%) <0.001
Central venous Catheter 46 (51%) 11 (44%) 35 (54%) 0.41
Gastro-esophageal reﬂux (GERD) 43 (48%) 21 (84%) 22 (34%) <0.001
Anti-reﬂux drugs (H2 Blockers) 58 (64%) 23 (92%) 35 (54%) <0.001
VAP* – 19 (76%) – –
Non-VAP 6 (24%)
Rate of HAP, n per 1000 patient-days – 13 – –
* VAP= ventilator-associated pneumonia.
102 M.G.E. Mansour, S. Bendarythe proportion of patients without HAP who were test nega-
tive. Predictive value of a positive test (PPV) is the proportion
of patients with positive tests who have disease. Predictive
value of a negative test (NPV) is the proportion of patients with
negative tests who do not have disease.
3. Results
3.1. Patients’ cohort characteristics
Ninety patients were admitted to the PICU during the study
period with mean age 21 ± 18.7 months, and males repre-
sented 49% of them. Their median PELOD score was 24 with
predicted mortality rate of 34%. Almost half of admitted cases
were admitted due to neurological emergency (coma and acute
ﬂaccid paralysis). Twenty-ﬁve patients developed HAP after
72 h of admission according to CPIS score. Nineteen patients
out of 25 had ventilator-associated pneumonia (VAP) (76%).
The recorded rate of HAP during the period of study was 13
cases per 1000 patient-days. Forty-four percent of patients
with HAP were less than 12 months, and 76% of them were
males. The distribution of the primary cause of PICU admis-
sion did not differ signiﬁcantly between patients who acquired
HAP and those who did not (Table 2).
3.2. Hospital-acquired pneumonia and its risk factors
Univariate analysis of different risk factors for the develop-
ment of HAP in our study revealed that mechanical ventilation(OR: 10; 95% CI: 3.2–30; p< 0.001), re-intubation (OR: 8.7;
95% CI: 2.3–31.5; p< 0.001), sedation by benzodiazipins and
opioids (OR: 4.3; 95% CI: 1.6–11.7; p < 0.01), nasogastric
feeding (OR: 7.1; 95% CI: 2.6–19.6; p< 0.001), gastro-esoph-
ageal reﬂux (OR: 10.3; 95% CI: 3.1–33.6; p< 0.001), and H2
Blockers (OR: 9.6; 95% CI: 2.14–45.3; p< 0.001) were signif-
icant risk factors for acquiring HAP (Table 3).
3.3. Clinical outcomes of hospital-associated pneumonia
Length of PICU stay was doubled in patients who acquired
HAP compared to patients without HAP (p< 0.05). Duration
of mechanical ventilation was signiﬁcantly longer in patients
with HAP (p< 0.01). HAP lead to 10% increment in the ac-
tual mortality rate above the predicted rate for the affected pa-
tients with signiﬁcant higher mortality than patients without
HAP (Table 2).
3.4. Etiologic diagnosis of HAP by multiplex-PCR
and bacterial culture
In our study, multiplex-PCR had a better diagnostic yield for
HAP than bacterial culture (sensitivity 76%, speciﬁcity 97%,
PPV 90%, NPV 93% vs. 24%, 92%, 55%, 79%, respectively,
for culture).
Acinetobacter was the most frequent organism isolated by
culture followed by K. pneumoniae and P. aeruginosa (Table
4). Multiplex-PCR signiﬁcantly increased the diagnostic yield
Table 4 Summary of m-PCR and bacterial culture results in endotracheal aspirate (ETA) and blood samples.
Variable ETA (n= 25) Blood samples (n= 25)
m-PCR Culture p m-PCR Culture p
Positive cases, n (%) 19 (76%) 6 (24%) <0.001 17 (68%) 2 (8%) <0.001
Streptococcus pneumoniae 2 (8%) – <0.16 – – <1.00
Methicillin-resistant Staphylococcus (MRSA) 6 (24%) – <0.01 2 (8%) – <0.16
Klebsiella pneumoniae 10 (40%) 5 (20%) 0.03 10 (40%) 1 (4%) <0.003
Mycoplasma pneumoniae 6 (24%) – <0.01 5 (20%) – 0.03
Chlamydia pneumoniae 1 (4%) – 0.3 1 (4%) – 0.32
Pseudomonas aeruginosa – 2 (8%) 0.16 – 1 (4%) 0.32
Legionella pneumophilia – – – –
Acinetobacter# – 7 (28%) – – 4 (16%) –
Acinetobacter# nd MRSA – – – – 1 (4%) –
Klebsiella pneumoniae and Pseudomonas aeruginosa – 1 (4%) – – – –
# Acinetobacter is not involved in the m-PCR panel.
Table 3 Risk factors for hospital-associated pneumonia.
Risk factor Odds ratio (OR) 95% CI* p-Value
Mechanical ventilation 10 3.2–30 <0.001
Re-intubation 8.7 2.3–31.5 <0.001
Sedation 4.3 1.6–11.7 <0.01
Nasogastric feeding 7.1 2.6–19.6 <0.001
Central venous catheter (CVC) 0.67 0.27–1.7 0.4
GERD 10.3 3.1–33.6 <0.001
H2 blockers 9.6 2.14–45.3 <0.001
* 95% CI = 95% Conﬁdence Interval.
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pneumoniae. Polymicrobial pneumonia was diagnosed in two
patients, where a combined growth of MRSA and Acinetobac-
ter was present in one patient and combined growth of P. aeru-
ginosa and K. pneumonia in another patient.4. Discussion
Both developed and resource-poor countries are faced with the
burden of health care-associated infections. In a World Health
Organization (WHO) cooperative study involving 55 hospitals
in 14 countries from four WHO regions, about 8.7% of hospi-
talized patients had nosocomial infections; among and repre-
sents the second most common nosocomial infection is HAP
[11]. The frequency of hospital-acquired pneumonia in our
PICU during study period was 13 per 1000 patient-days with
associated mortality rate of 56% with predominance of
Gram-negative pathogens; K. pneumoniae was diagnosed in
40%, Acinetobacter in 28% with MRSA in 24%. A 6-year sur-
veillance study from 2002 to 2007 involving intensive care units
in Latin America, Asia, Africa, and Europe, using Center for
Disease Control’s NNIS deﬁnitions, revealed higher rates of
HAP and VAP than those of comparable United States ICUs.
The survey also reported higher frequencies of mortalities
associated with MRSA, Enterobacter species, and P. aerugin-
osa [12]. Patra et al. [13] reported that VAP constituted 76%
of patients with hospital-acquired pneumonia and represented
the most frequent nosocomial infection in intensive care units
(80%) with an overall mortality of nosocomial pneumonia
reaching 60%; all were secondary to Gram-negative infectionswith Pseudomonas contributing to 57.1% of deaths followed
by Klebsiella, Escherichia coli and Acinetobacter. The increas-
ing incidence of infections caused by antibiotic-resistant patho-
gens contributes to the emerging seriousness of these infections
with expected higher mortality rate. Numerous studies have
demonstrated that severe underlying illness predisposes
patients in the ICU to the development of pneumonia and con-
tribute to the associated high mortality rates [14].
In our study; the mean length of stay was doubled following
HAP together with 50% increment in the mean duration of
mechanical ventilation days. In another study, HAP lengthens
the hospital stay by 7–9 days and is associated with a higher
cost of medical care [14]. Fifty-two percent of enrolled patients
with HAP in our study were admitted primarily to the PICU
due to neurological emergencies (e.g. acute ﬂaccid paralysis
with rapid progression to involve respiratory muscles, status
epileptics and coma). This group of patients had major neu-
ro-critical dependency during their stay due to muscle paraly-
sis. In Chiang Mai University Hospital, a tertiary care center,
the most common indication for PICU admission was respira-
tory failure [15], while in a tertiary teaching hospital in south-
ern Brazil, bronchiolitis was reported to be the most frequent
cause for PICU admission (77.6%) [16]. It is noted in our study
that 44% of patients acquired HAP were less than 12 months
and this may be explained by the vulnerability of this age
group to life-threatening diseases. Seventy-six percent of them
were males while females represent 24%, which raised the
question of whether males are more susceptible to progression
of illness and more vulnerable to critical illness. The same ﬁnd-
ing was noted by a study done by Khaled Amro [17], in a refer-
ral hospital of South Jordan where 34.4% of enrolled patients
104 M.G.E. Mansour, S. Bendarywith nosocomial pneumonia were less than one year age. Boys
represent 57% of total number of patients enrolled by Sriniva-
san et al. [18] in a tertiary pediatric care center. Another study
done by Martinbiancho et al. [19] also recorded a higher inci-
dence of HAP among (males 63%).
Many risk factors may favor or contribute to the develop-
ment of nosocomial pneumonia. In our study, gastro-esopha-
geal reﬂux disease (GERD) and treatment with H2 Blockers,
mechanical ventilation, nasogastric tube feeding, and use of
benzodiazepines and opioids as sedative drugs, and re-intuba-
tion were signiﬁcant risk factors for HAP. The primary route
through which organisms enter the lower airways is via aspira-
tion of colonized oropharyngeal secretions [19]. Micro-aspira-
tion plays a central role in the pathogenesis of nosocomial
pneumonia among critically ill patients especially those with
nasogastric feeding and on mechanical ventilation (MV). The
oropharynx of hospitalized patients becomes colonized with
aerobic gram-negative bacteria within few days of admission.
Therefore, nosocomial pneumonia is caused predominantly
by the Gram-negative bacilli [20]. Within 12 h of intubation;
a bioﬁlm is formed around the endotracheal tube which con-
tains large amounts of bacteria that can be disseminated into
the lungs by ventilator-induced breaths. This bioﬁlm may be-
come dislodged during suctioning, or repositioning of the
endotracheal tube [21]. Impaired muco-ciliary clearance with
mucosal injury and glottic dysfunction associated with pro-
longed intubation further aggravates the risk of VAP with
re-intubation [12]. Daily interruption of sedative infusions in
critically ill patients receiving mechanical ventilation decreases
the duration of mechanical ventilation and reduces the length
of ICU stay. Consequently, this practice can be considered
worthy for reducing VAP risk and its occurrence [21–22].
The causative organisms vary according to the patients’
medical condition, demographics, methods of diagnosis, the
durations of hospital and ICU stays, the antibiotic policy
and the prior exposure to antimicrobials. All these factors sig-
niﬁcantly inﬂuence the distribution patterns of etiologic agents
from one ICU to another [23]. The most frequent organisms
detected in our study were K. pneumoniae (40%), Acinetobacter
(28%) and followed by M. pneumoniae (24%) and MRSA
(24%), while the least common isolates were Streptococcus
pneumoniae (8%) and C. pneumoniae (4%).
Acinetobacter baumannii is now recognized to be capable of
causing life-threatening infections including pneumonia [24].
This appears to be due to their ability to survive on health-care
workers’ hands and environmental surfaces and their intrinsic
resistance to many common antibiotics, rather than any intrin-
sic virulence factors [25]. Antibiotic therapy and critical illness
can suppress the normal bacterial ﬂora and lead to an over-
growth of Enterobacteriaceae like K. pneumoniae in the respi-
ratory tracts. The most concerning is the acquisition of
extended-spectrum b-lactamases that render the bacteria resis-
tant to penicillin and cephalosporin antibiotics [26]. Extended
spectrum b-lactamase (ESBL) producing K. pneumoniae may
cause serious nosocomial infections especially in critically ill
patients. Numerous outbreaks have been described with
ICU-acquired ESBL-producing K. pneumoniae where infection
increased from a baseline rate of 0.44 cases per 1000 patient-
days to 6.86 cases per 1000 patient-days [26].
Streptococcus pneumoniae was not a common ﬁnding in our
study because it predominates in the early days after intubation
and is rapidly cleared after beginning antibiotic therapy as theisolates remain susceptible to achievable concentrations of tra-
ditional lactam antibiotics [27]. MRSA was detected as a caus-
ative agent for HAP in 24% of cases in our study by m-PCR.
Staphylococcus aureus (both Methicillin sensitive and resistant
strains), constitutes the most frequently isolated pathogen in
the ICU. The incidence of MRSA as a cause of VAP was 12–
15%, but increased to approximately 30% in patients with pro-
longed mechanical ventilation and prior antibiotic therapy [28].
Methicillin resistance in Staphylococcus aureus has the particu-
larity to add multiple antimicrobial resistances up to 80% of
macrolide resistance and 90% of quinolone resistance [29].
Those strains with mecA are resistant to all commercially avail-
able b-lactams, with considerable country-to-country variabil-
ity [29]. Traditionally, we are not used to ﬁnd M. pneumoniae
in our bacteriological cultures as a causative pathogen of
HAP, but in this study it was detected in 24% of patients and
diagnosed only by m-PCR. Since that, we consideredM. pneu-
moniae in the etiologic diagnosis of HAP in critically ill patients
who develop nosocomial pneumonia within the ﬁrst week after
intubation [12,28,29], and our therapeutic regimen should in-
clude these ﬁndings. Altogether with VAP task forces, the
emergence of resistance is a concern for intensive care special-
ists worldwide thus it is imperative for investigators from differ-
ent countries and regions to exchange precise and updated
epidemiological data on the encountered HAP and VAP.
In our study, m-PCR optimized the diagnosis and manage-
ment of hospital-acquired pneumonia over bacterial culture.
The use of PCR leads to an increase in diagnostic sensitivity,
especially in micro-organisms that cannot be easily cultured
and in case of a low burden of micro-organisms with previous
antibiotic therapy [30]. This is in agreement with Stra˚lin et al.
[31], who recommended multiplex PCR to be a useful etiolog-
ical diagnostic tool in lower respiratory tract infection patients,
particularly in those treated with antibiotics. The same was
suggested early by Hendolin et al. [32] where multiplex PCR
method improved the rapid and simultaneous detection rate
of four bacterial pathogens in upper respiratory tract infec-
tions signiﬁcantly compared to that of the conventional culture
method.5. Conclusion
Our study is one of the few prospective observational studies in
critically ill children describing the risk factors and outcomes of
hospital-acquired pneumonia.We found that gastro-esophageal
reﬂux, treatment with H2 blockers, mechanical ventilation,
nasogastric feeding, use of sedative drugs and re-intubation
are signiﬁcant risk factors forHAP in our setting. These ﬁndings
need to be conﬁrmed in larger, multicenter studies to clarify risk
factors and the impact of prevention strategies. Our study shows
that HAP negatively impacts clinical and economic outcomes in
critically ill pediatric patients by prolonging the length of
mechanical ventilation and ICU stay and may increase total
hospital charges and absolute hospital mortality rate. More-
over, m-PCR optimized the emergency diagnosis of hospital-
acquired pneumonia over bacterial culture, especially in
micro-organisms that cannot be easily cultured. Though the
bacterial pattern of HAP in our study may differ from other
countries, it is imperative for investigators from different
regions to exchange precise and updated epidemiological data
about HAP concerns.
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